Nucleic acids encoding anti-neonatal Fc receptor (FcRn) antibodies
The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
1. An isolated nucleic acid or nucleic acids comprising a nucleotide sequence that encodes an anti-neonatal Fc receptor (FcRn) antibody comprising a light chain variable region (V L ) and a heavy chain variable region (V H ), wherein the antibody binds to human FcRn;
wherein the V L comprises:
(i) a V L CDR1 comprising the amino acid sequence of SEQ ID NO: 14;
(ii) a V L CDR2 comprising the amino acid sequence of SEQ ID NO: 15; and
(iii) a V L CDR3 comprising the amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 13; and
wherein the V H comprises:
(i) a V H CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(ii) a V H CDR2 comprising the amino acid sequence of SEQ ID NO: 23; and
(iii) a V H CDR3 comprising the amino acid sequence of SEQ ID NO: 24.
2. The isolated nucleic acid(s) of claim 1 , wherein the V L of the isolated antibody comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11.
3. The isolated nucleic acid(s) of claim 1 , wherein the V H of the isolated antibody comprises the amino acid sequence of SEQ ID NO: 9.
4. The isolated nucleic acid(s) of claim 1 , wherein the isolated antibody is a human or humanized antibody or is non-immunogenic in a human.
5. The isolated nucleic acid(s) of claim 4 , wherein the isolated antibody comprises a human antibody framework region.
6. The isolated nucleic acid(s) of claim 1 , wherein the isolated antibody is a murine antibody.
7. The isolated nucleic acid(s) of claim 1 , wherein the isolated antibody is chimeric.
8. The isolated nucleic acid(s) of claim 1 , wherein the isolated antibody is a full-length antibody.
9. The isolated nucleic acid(s) of claim 1 , wherein the isolated antibody is selected from the group consisting of Fab, F(ab)′2, Fv, and scFv.
10. A vector or vectors comprising the nucleic acid(s) of claim 1 .
11. The vector or vector(s) of claim 10 , wherein the vector is an expression vector.
12. An isolated host cell or host cells comprising the vector(s) of claim 10 .
13. The isolated host cell(s) of claim 12 , wherein the cell is selected from the group consisting of: a mammalian cell, a bacterial cell, a yeast cell, an insect cell, or a plant cell.
14. The isolated host cell(s) of claim 13 , wherein the mammalian cell is selected from the group consisting of: a Chinese Hamster Ovarian (CHO) cell, a NSO myeloma cell, a SP2 cell, a COS cell, or a mammary epithelial cell.
15. A method of producing an anti-neonatal Fc receptor (FcRn) antibody that binds to human FcRn, comprising
culturing the isolated host cell of claim 12 in a culture medium, thereby producing the antibody.
16. The method of claim 15 , wherein the isolated host cell is a mammalian cell.
17. The method of claim 16 , wherein the isolated host cell is a Chinese Hamster Ovarian (CHO) cell.
18. The method of claim 15 , further comprising recovering the antibody from the culture medium.
19. The method of claim 15 , further comprising purifying the antibody.